The antibody drug conjugates contract manufacturing market size is estimated at USD 12.02 billion in 2026, and is expected to reach USD 20.54 billion by 2031, at a CAGR of 11.31% during the forecast period (2026-2031). This report is Segmented by Linker Type (Cleavable [Acid-Labile and More], Non-Cleavable), Therapeutic Area (Hematologic Cancers [Multiple Myeloma and More], and More), Phase (Pre-Clinical, and More), Service Type (Process Development, Analytical/QC, CGMP Conjugation, Fill-Finish), and Geography (North America, and More). Market Forecasts are Provided in Terms of Value (USD).
CDMOs have invested in flexible conjugation skids that switch between cleavable and non-cleavable chemistries without lengthy changeovers. Lonza’s XpressCys system allows a sponsor to move from early discovery to GMP within a single platform, shortening time to clinic. Cleavable linkers remain essential for hematologic cancers where rapid intracellular release is desirable; however, solid-tumor programs increasingly demand acid-labile and protease-sensitive designs to localize drug activity.
Solid tumors generated 57.94% of 2025 revenue, but autoimmune and infectious-disease projects are projected to log a 14.45% CAGR to 2031. The antibody drug conjugates contract manufacturing market size tied to autoimmune indications is therefore widening faster than oncology growth alone. Sponsors initiated 18 early-phase autoimmune trials in 2024, betting that selective B-cell ablation can deliver durable remission with intermittent dosing. Solid-tumor demand remains robust, driven by HER2-low, TROP2, and Nectin-4 targets, yet market planners now view non-oncology as the top incremental growth driver.
The autoimmune push requires segregated manufacturing to avoid cross-contamination with high-potency oncology payloads, adding 15-20% to contract pricing. CDMOs willing to dedicate cleanrooms to non-oncology customers stand to command premium margins. Infectious-disease ADCs are nascent, but early venture investment signals future diversification.
Asia-Pacific is set to post a 14.04% CAGR, the fastest among regions. Samsung Biologics’ 256 kL Plant 5 and AGC Biologics’ Yokohama facility together add 350 kL of capacity by 2026, equal to 15% of global supply. Lower labor costs and supportive government incentives underpin competitive pricing, drawing late-stage programs from cost-conscious sponsors.
Europe captured 28% of 2025 revenue, led by Germany, Switzerland, and the United Kingdom. The revised Annex 1 rules have improved operating margins by lowering cleanroom capital outlays, yet divergent post-Brexit filing rules add complexity. Smaller European economies lag due to higher labor costs and less generous R&D tax credits.
Global Antibody Drug Conjugates Contract Manufacturing Market Trends and Insights
Surging Oncology Incidence & Larger Addressable Patient Pool
Global cancer cases reached 20 million in 2024, and WHO projects a rise to 35 million by 2050, sustaining demand for safer targeted therapies.Enhertu’s 2024 approval for HER2-low breast cancer validated biomarker-driven expansion and added 1.2 million eligible patients per year. CDMOs responded by installing multi-product conjugation suites sized for 50-200 kg batches, bridging late-stage and early commercial needs, exemplified by Lonza’s twin 1,200 L reactors at Visp scheduled for 2028 service.Big-Pharma Pivot to Outsourced Biologics Manufacturing
A BCG review found that 70-80% of developers lacked in-house conjugation capacity in 2024. Pfizer halted a USD 350 million build in Everett and instead signed a USD 1.24 billion contract with Samsung Biologics, prioritizing external scale while focusing internal plants on development. AstraZeneca’s Singapore site, slated for 2029, will cover only early phase work, reserving commercial supply for CDMOs.Cytotoxic Payload Supply Bottlenecks & Hazardous-Material Logistics
Fewer than 10 suppliers produce GMP auristatins and maytansinoids, with 18-month lead times in 2024. New IATA rules reclassifying certain payloads as Category 1A carcinogens raised air-freight costs by up to 70%. Daiichi Sankyo’s Shanghai payload plant, set for 2030, reflects vertical-integration efforts to mitigate shortages.Other drivers and restraints analyzed in the detailed report include:
- Expansion of ADC Clinical Pipeline Beyond Oncology
- Capacity Constraints at HPAPI Facilities Triggering Premium Pricing
- High COGS Owing to Multi-Modal Analytical Release Requirements
Segment Analysis
Cleavable linkers controlled 66.37% of antibody drug conjugates contract manufacturing market share in 2025, yet non-cleavable systems are forecast to grow 15.25% annually through 2031, outstripping the overall market. The antibody drug conjugates contract manufacturing market size tied to non-cleavable constructs will therefore expand more quickly than cleavable revenue during the period. Developers favor non-cleavable designs for better systemic stability, releasing payload only after lysosomal degradation. Enhertu’s USD 3.1 billion 2024 sales proved that a hybrid approach using membrane-permeable toxins can offset the lower bystander effect seen in first-generation non-cleavables.CDMOs have invested in flexible conjugation skids that switch between cleavable and non-cleavable chemistries without lengthy changeovers. Lonza’s XpressCys system allows a sponsor to move from early discovery to GMP within a single platform, shortening time to clinic. Cleavable linkers remain essential for hematologic cancers where rapid intracellular release is desirable; however, solid-tumor programs increasingly demand acid-labile and protease-sensitive designs to localize drug activity.
Solid tumors generated 57.94% of 2025 revenue, but autoimmune and infectious-disease projects are projected to log a 14.45% CAGR to 2031. The antibody drug conjugates contract manufacturing market size tied to autoimmune indications is therefore widening faster than oncology growth alone. Sponsors initiated 18 early-phase autoimmune trials in 2024, betting that selective B-cell ablation can deliver durable remission with intermittent dosing. Solid-tumor demand remains robust, driven by HER2-low, TROP2, and Nectin-4 targets, yet market planners now view non-oncology as the top incremental growth driver.
The autoimmune push requires segregated manufacturing to avoid cross-contamination with high-potency oncology payloads, adding 15-20% to contract pricing. CDMOs willing to dedicate cleanrooms to non-oncology customers stand to command premium margins. Infectious-disease ADCs are nascent, but early venture investment signals future diversification.
Complete Report Scope:
- By Linker Type
- Cleavable
- Acid-labile
- Protease-cleavable
- Disulfide-cleavable
- Non-cleavable
- Cleavable
- By Therapeutic Area
- Hematologic Cancers
- Multiple Myeloma
- Lymphoma
- Solid Tumours
- Breast
- Lung
- Gastric & GI
- Other Indications (Auto-immune, Infectious)
- Hematologic Cancers
- By Phase
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Commercial
- By Service Type
- Process / Cell-line Development
- Analytical, Bio-assay & QC
- cGMP Conjugation & Drug-linker Manufacturing
- Fill-Finish & Packaging
- Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 44.68% of revenue in 2025, powered by a dense innovator base and ongoing brownfield expansions in Missouri, North Carolina, and Massachusetts. The region’s regulatory environment supports first-to-trial ambitions, keeping average project timelines shorter than in Europe. The antibody drug conjugates contract manufacturing market share held by North America will erode slightly as APAC capacity comes online, but absolute revenue will rise given healthy underlying demand.Asia-Pacific is set to post a 14.04% CAGR, the fastest among regions. Samsung Biologics’ 256 kL Plant 5 and AGC Biologics’ Yokohama facility together add 350 kL of capacity by 2026, equal to 15% of global supply. Lower labor costs and supportive government incentives underpin competitive pricing, drawing late-stage programs from cost-conscious sponsors.
Europe captured 28% of 2025 revenue, led by Germany, Switzerland, and the United Kingdom. The revised Annex 1 rules have improved operating margins by lowering cleanroom capital outlays, yet divergent post-Brexit filing rules add complexity. Smaller European economies lag due to higher labor costs and less generous R&D tax credits.
List of Companies Covered in this Report:
- Abzena
- AGC Biologics
- Ajinomoto Bio-Pharma Services
- Axplora (Novasep)
- Bora Biologics
- Cambrex Corp.
- CARBOGEN AMCIS
- Catalent
- Cerbios-Pharma
- Emergent Bio Solutions
- FUJIFILM
- Lonza Group
- Merck KGaA (MilliporeSigma)
- Oncotec Pharma Produktion
- Piramal Group
- Recipharm
- Samsung Group
- Sterling Pharma Solutions
- Thermo Fisher Scientific
- Wuxi Biologics
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abzena
- AGC Biologics
- Ajinomoto Bio-Pharma Services
- Axplora (Novasep)
- Bora Biologics
- Cambrex Corp.
- CARBOGEN AMCIS
- Catalent Inc.
- Cerbios-Pharma SA
- Emergent BioSolutions
- Fujifilm Diosynth Biotechnologies
- Lonza Group
- Merck KGaA (MilliporeSigma)
- Oncotec Pharma Produktion
- Piramal Pharma Solutions
- Recipharm
- Samsung Biologics
- Sterling Pharma Solutions
- Thermo Fisher Scientific
- WuXi Biologics
